FDG-PET imaging in the management of non-small-cell lung cancer

被引：9
|
作者：
Salminen, E
Mac Manus, M
机构：
[1] Turku Univ Hosp, Dept Radiotherapy & Oncol, FIN-20520 Turku, Finland
[2] Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia
来源：
ANNALS OF ONCOLOGY | 2002年 / 13卷 / 03期
关键词：
FDG-PET; non-small-cell lung cancer; outcome; staging; treatment;
D O I：
10.1093/annonc/mdf106
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Lung cancer is currently the leading cause of cancer-related death in both men and women in most Western countries. Tumour stage is the strongest prognostic factor and the most important parameter guiding treatment decision making. Metabolic positron emission tomography imaging with fluorodeoxyglucose (FDG-PET) has consistently proved superior to conventional imaging for staging of non-small-cell lung cancer and provides information of greater prognostic significance than can be obtained using conventional approaches. FDG-PET has been approved in the USA. Germany and the UK as a basic and invaluable tool in the management of lung cancer.
引用
收藏
页码：357 / 360
页数：4
相关论文
共 50 条
  • [31] Staging of non-small-cell lung cancer with FDG-PET/CT: Is there a correlation of morphologic tumor characteristics and metabolic activity?
    Kuehl, Hilmar
    Sommerwerck, Urte
    Mueller, Stefan
    van Eijk, Tina
    Bockisch, Andreas
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [32] The prognostic relevance of response evaluation to chemotherapy by FDG-PET/CT in patients with metastatic non-small-cell lung cancer
    Selcuk, N. A.
    Uluc, B. O.
    Ordu, C.
    Akosman, C.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2011, 38 : S359 - S360
  • [33] The effect of FDG-PET on the stage distribution of non-small cell lung cancer
    Morgensztern, Daniel
    Goodgame, Boone
    Baggstrom, Maria Q.
    Govindan, Ramaswamy
    Gao, Feng
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) : 135 - 139
  • [34] The Prognostic Significance Of FDG-PET In Advanced Non-Small Cell Lung Cancer
    Hyun, D. S.
    Kim, K. C.
    Lee, S. C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [35] FDG-PET for monitoring of neoadjuvant radiochemotherapy in non small cell lung cancer (NSCLC).
    Eschmann, SM
    Thelen, MH
    Dohmen, BM
    Friedel, G
    Toomes, H
    Bamberg, M
    Bares, R
    JOURNAL OF NUCLEAR MEDICINE, 2000, 41 (05) : 113P - 113P
  • [36] Use of PET in the management of non-small-cell lung cancer in Canada
    Vorauer, E.
    Louzado, C.
    DeCaria, K.
    Hernandez, J.
    Rahal, R.
    Niu, J.
    Lockwood, G.
    Bryant, H.
    CURRENT ONCOLOGY, 2014, 21 (06) : 337 - 339
  • [37] Effectiveness of whole-body FDG PET imaging in staging of non-small-cell lung cancer (NSCLC)
    Steinert, HC
    von Schulthess, GK
    Weder, W
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 80P - 80P
  • [38] FDG PET and CT radiomics in diagnosis and prognosis of non-small-cell lung cancer
    Hannequin, Pascal
    Decroisette, Chantal
    Kermanach, Pascale
    Berardi, Giulia
    Bourbonne, Vincent
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (10) : 2051 - +
  • [39] Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma
    Gambhir, SS
    Hoh, CK
    Phelps, ME
    Madar, I
    Maddahi, J
    JOURNAL OF NUCLEAR MEDICINE, 1996, 37 (09) : 1428 - 1436
  • [40] Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma
    Makler, PT
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (07) : 1173 - 1173
12345